Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.68 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9237631 | 1.00 | CHRNB4 (0.68) | CHRNB4CHRNA3LTA4H | |
| Hydrochloric Acid SCHEMBL9241795 | 0.99 | CHRNB4 (0.67) | CHRNB4CHRNA3LTA4H | |
| Hydrochloric Acid SCHEMBL9241805 | 0.99 | CHRNB4 (0.67) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL11447605 | 0.88 | CHRNB4 (0.53) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL6611673 | 0.84 | LTA4H (0.50) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL8290262 | 0.83 | LTA4H (0.66) | CHRNA3LTA4H | |
| SCHEMBL7901523 | 0.83 | LTA4H (0.79) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL4155746 | 0.83 | LTA4H (0.79) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL5332805 | 0.83 | LTA4H (0.79) | CHRNB4CHRNA3LTA4H | |
| Hydrochloric Acid SCHEMBL4742124 | 0.82 | LTA4H (0.77) | CHRNB4CHRNA3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | claimed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CHRNB4 1794/4885CHRNA3 2401/4885LTA4H 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.